deltatrials
Completed OBSERVATIONAL NCT02374450

A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine

A Prospective Study to Estimate the Incidence of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Infants and Young Children in Sub-Saharan Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine

Sponsor: Agence de Médecine Préventive, France

Conditions Malaria
Interventions Blood collection
Updated 15 times since 2017 Last updated: Sep 13, 2024 Started: Oct 5, 2015 Primary completion: Aug 2, 2022 Completion: Aug 2, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A observational or N/A phase clinical study on Malaria, this trial is completed. The trial is conducted by Agence de Médecine Préventive, France and has accumulated 15 data snapshots since 2015. Infectious disease trials contribute critical data for public health response and treatment development.

Status Flow

~Jan 2017 – ~Apr 2017 · 3 months · monthly snapshot~Apr 2017 – ~Dec 2017 · 8 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jun 2019 · 12 months · monthly snapshot~Jun 2019 – ~Jun 2020 · 12 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~May 2021 · 4 months · monthly snapshot~May 2021 – ~Nov 2021 · 6 months · monthly snapshot~Nov 2021 – ~Jun 2022 · 7 months · monthly snapshot~Jun 2022 – ~Feb 2023 · 8 months · monthly snapshot~Feb 2023 – ~Jul 2024 · 17 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Feb 2025 · 4 months · monthly snapshot~Feb 2025 – present · 19 months · monthly snapshot

Change History

15 versions recorded
  1. Feb 2025 — Present [monthly]

    Completed

  2. Oct 2024 — Feb 2025 [monthly]

    Completed

  3. Sep 2024 — Oct 2024 [monthly]

    Completed

  4. Jul 2024 — Sep 2024 [monthly]

    Completed

  5. Feb 2023 — Jul 2024 [monthly]

    Completed

    Status: Active Not RecruitingCompleted

Show 10 earlier versions
  1. Jun 2022 — Feb 2023 [monthly]

    Active Not Recruiting

  2. Nov 2021 — Jun 2022 [monthly]

    Active Not Recruiting

  3. May 2021 — Nov 2021 [monthly]

    Active Not Recruiting

  4. Jan 2021 — May 2021 [monthly]

    Active Not Recruiting

  5. Jun 2020 — Jan 2021 [monthly]

    Active Not Recruiting

    Status: RecruitingActive Not Recruiting

  6. Jun 2019 — Jun 2020 [monthly]

    Recruiting

    Phase: NANone

  7. Jun 2018 — Jun 2019 [monthly]

    Recruiting NA

  8. Dec 2017 — Jun 2018 [monthly]

    Recruiting NA

  9. Apr 2017 — Dec 2017 [monthly]

    Recruiting NA

  10. Jan 2017 — Apr 2017 [monthly]

    Recruiting NA

    First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Agence de Médecine Préventive, France
  • Clinical Laboratory Services
  • GlaxoSmithKline
  • Iqvia Pty Ltd
  • PATH
  • Parexel
  • Réseau en Afrique Francophone pour la Télémédecine,
Data source: GlaxoSmithKline

For direct contact, visit the study record on ClinicalTrials.gov .